Poxel Announces its Participation in Upcoming Investor and Scientific Conferences
31 Mai 2022 - 6:56PM
Business Wire
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage
biopharmaceutical company developing innovative treatments for
chronic serious diseases with metabolic pathophysiology, including
non-alcoholic steatohepatitis (NASH) and rare metabolic disorders,
today announces that the Poxel team will participate in several
upcoming investor and scientific conferences in June 2022.
- Jefferies 2022 Global Healthcare Conference (in person) -
New York, New York, USA Date: June 8-10, 2022 Thomas
Kuhn, CEO and other members of the Poxel management team will be
available for one-on-one in-person meetings on June 9-10, 2022. The
Company presentation is scheduled for June 10 at 11:00am ET.
- JMP Securities 2022 Life Science Conference (in person) -
New York, New York, USA Date: June 15-16, 2022 Thomas Kuhn, CEO
and other members of the Poxel management team will be available
for one-on-one in-person meetings on June 16, 2022. The Company
presentation is scheduled for June 16 at 12:30pm ET.
- 2022 United Leukodystrophy Foundation Scientific Symposium -
Itasca, Illinois, USA Date: June 23-25, 2022 David
Moller, Executive Vice President, Chief Scientific Officer of
Poxel, will present on the Company’s adrenoleukodystrophy (ALD)
clinical program on Friday, June 24. Poxel is a sponsor of this
scientific symposium.
- 8th Congress of the European Academy of Neurology (in
person) – Vienna, Austria Date: June 25-28, 2022 Poxel
will present an e-poster on its drug candidate PXL770 entitled:
"Potential Therapeutic Utility of Direct AMP Kinase Activation for
X-Linked Adrenoleukodystrophy (ALD)". Also, Sophie Bozec, PhD,
Senior Vice President, R&D Pharmacology and Scientific
Communication, will deliver a presentation: “Deuterium-Stabilized
(R)-Pioglitazone, PXL065, for Treatment of X-Linked
Adrenoleukodystrophy (ALD)”.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company
developing innovative treatments for chronic serious diseases
with metabolic pathophysiology, including non-alcoholic
steatohepatitis (NASH) and rare disorders. Poxel has clinical
and earlier-stage programs from its adenosine
monophosphate-activated protein kinase (AMPK) activator and
deuterated TZD platforms targeting chronic and rare metabolic
diseases. For the treatment of NASH, PXL065
(deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2
trial (DESTINY-1). PXL770, a first-in-class direct AMPK
activator, has successfully completed a Phase 2a proof-of-concept
trial for the treatment of NASH, which met its objectives. For the
rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the
company intends to initiate Phase 2a proof of concept studies with
PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN).
TWYMEEG® (Imeglimin), Poxel’s first-in-class lead product
that targets mitochondrial dysfunction, has been approved and
launched for the treatment of type 2 diabetes in Japan. Poxel
expects to receive royalties and sales-based payments from Sumitomo
Pharma. Poxel has a strategic partnership with Sumitomo Pharma for
Imeglimin in Japan, China, South Korea, Taiwan and nine other
Southeast Asian countries. The Company intends to generate further
growth through strategic partnerships and pipeline development.
Listed on Euronext Paris, Poxel is headquartered in Lyon, France,
and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220531005858/en/
Contacts - Investor relations / Media
Aurélie Bozza Investor Relations & Communication Senior
Director aurelie.bozza@poxelpharma.com +33 6 99 81 08 36
Elizabeth Woo Senior Vice President, Investor Relations &
Communication elizabeth.woo@poxelpharma.com
NewCap Emmanuel Huynh or Arthur Rouillé poxel@newcap.eu +33 1 44
71 94 94
Poxel (EU:POXEL)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Poxel (EU:POXEL)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024